It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.
The study is aimed to determine if oral administration of Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis. Subjects will be instructed to take 600 mg tablets of extended release Mucinex® twice a day (total dose is 1.2 g/day) for 4 weeks.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
Mucinex®
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States
Change in Number of Corneal Filaments
Change was calculated as the value after receiving treatment with guaifenesin for 4 weeks minus the value at baseline.
Time frame: baseline (day 1) and week 4
Change in OSDI Score
Change was calculated as the value after receiving treatment with guaifenesin for 4 weeks minus the value at baseline. Total score ranges from 0-100. Lower OSDI scores means subjects are experiencing low ocular discomfort. High OSDI scores means subjects are experiencing high ocular discomfort.
Time frame: baseline (day 1) and week 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.